vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与DigitalOcean Holdings, Inc.（DOCN）财务数据对比。点击上方公司名可切换其他公司
DigitalOcean Holdings, Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.5倍（$242.4M vs $156.4M），DigitalOcean Holdings, Inc.同比增速更快（18.3% vs 7.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 14.5%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
BCRX vs DOCN — 直观对比
营收规模更大
DOCN
是对方的1.5倍
$156.4M
营收增速更快
DOCN
高出10.8%
7.5%
两年增速更快
BCRX
近两年复合增速
14.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $242.4M |
| 净利润 | — | $25.7M |
| 毛利率 | — | 58.7% |
| 营业利润率 | 13.6% | 16.0% |
| 净利率 | — | 10.6% |
| 营收同比 | 7.5% | 18.3% |
| 净利润同比 | — | 40.5% |
| 每股收益（稀释后） | $0.00 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXDOCN
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $242.4M | ||
| Q3 25 | $159.4M | $229.6M | ||
| Q2 25 | $163.4M | $218.7M | ||
| Q1 25 | $145.5M | $210.7M | ||
| Q4 24 | $131.5M | $204.9M | ||
| Q3 24 | $117.1M | $198.5M | ||
| Q2 24 | $109.3M | $192.5M |
净利润BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $25.7M | ||
| Q3 25 | $12.9M | $158.4M | ||
| Q2 25 | $5.1M | $37.0M | ||
| Q1 25 | $32.0K | $38.2M | ||
| Q4 24 | $-26.8M | $18.3M | ||
| Q3 24 | $-14.0M | $32.9M | ||
| Q2 24 | $-12.7M | $19.1M |
毛利率BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 58.7% | ||
| Q3 25 | 98.6% | 59.6% | ||
| Q2 25 | 98.3% | 59.9% | ||
| Q1 25 | 96.9% | 61.4% | ||
| Q4 24 | 95.4% | 57.1% | ||
| Q3 24 | 97.3% | 60.2% | ||
| Q2 24 | 98.4% | 61.0% |
营业利润率BCRXDOCN
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 16.0% | ||
| Q3 25 | 18.6% | 19.6% | ||
| Q2 25 | 18.2% | 16.3% | ||
| Q1 25 | 14.6% | 17.9% | ||
| Q4 24 | -3.4% | 15.9% | ||
| Q3 24 | 6.6% | 12.4% | ||
| Q2 24 | 8.0% | 11.6% |
净利率BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 10.6% | ||
| Q3 25 | 8.1% | 69.0% | ||
| Q2 25 | 3.1% | 16.9% | ||
| Q1 25 | 0.0% | 18.1% | ||
| Q4 24 | -20.4% | 8.9% | ||
| Q3 24 | -12.0% | 16.6% | ||
| Q2 24 | -11.6% | 9.9% |
每股收益（稀释后）BCRXDOCN
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.23 | ||
| Q3 25 | $0.06 | $1.51 | ||
| Q2 25 | $0.02 | $0.39 | ||
| Q1 25 | $0.00 | $0.39 | ||
| Q4 24 | $-0.13 | $0.21 | ||
| Q3 24 | $-0.07 | $0.33 | ||
| Q2 24 | $-0.06 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $254.5M |
| 总债务越低越好 | — | $1.3B |
| 股东权益账面价值 | — | $-28.7M |
| 总资产 | $465.1M | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXDOCN
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $254.5M | ||
| Q3 25 | $212.9M | $236.6M | ||
| Q2 25 | $260.0M | $387.7M | ||
| Q1 25 | $295.1M | $360.4M | ||
| Q4 24 | $320.9M | $428.4M | ||
| Q3 24 | $96.8M | $439.9M | ||
| Q2 24 | $78.4M | $443.1M |
总债务BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $-28.7M | ||
| Q3 25 | $-387.9M | $-69.6M | ||
| Q2 25 | $-421.6M | $-175.2M | ||
| Q1 25 | $-451.9M | $-210.7M | ||
| Q4 24 | $-475.9M | $-203.0M | ||
| Q3 24 | $-468.6M | $-211.7M | ||
| Q2 24 | $-475.6M | $-253.8M |
总资产BCRXDOCN
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.8B | ||
| Q3 25 | $446.4M | $1.7B | ||
| Q2 25 | $457.2M | $1.7B | ||
| Q1 25 | $480.0M | $1.6B | ||
| Q4 24 | $490.4M | $1.6B | ||
| Q3 24 | $491.3M | $1.5B | ||
| Q2 24 | $472.4M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $57.3M |
| 自由现金流经营现金流 - 资本支出 | — | $31.1M |
| 自由现金流率自由现金流/营收 | — | 12.8% |
| 资本支出强度资本支出/营收 | — | 10.8% |
| 现金转化率经营现金流/净利润 | — | 2.23× |
| 过去12个月自由现金流最近4个季度 | — | $180.5M |
8季度趋势，按日历期对齐
经营现金流BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $57.3M | ||
| Q3 25 | $41.6M | $95.8M | ||
| Q2 25 | $41.3M | $92.4M | ||
| Q1 25 | $-27.5M | $64.1M | ||
| Q4 24 | $-5.2M | $71.3M | ||
| Q3 24 | $8.2M | $73.4M | ||
| Q2 24 | $-1.4M | $71.3M |
自由现金流BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $31.1M | ||
| Q3 25 | $40.3M | $88.0M | ||
| Q2 25 | $41.1M | $59.3M | ||
| Q1 25 | $-27.7M | $2.1M | ||
| Q4 24 | $-5.9M | $26.1M | ||
| Q3 24 | $8.2M | $16.0M | ||
| Q2 24 | $-1.5M | $39.5M |
自由现金流率BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 12.8% | ||
| Q3 25 | 25.3% | 38.3% | ||
| Q2 25 | 25.2% | 27.1% | ||
| Q1 25 | -19.0% | 1.0% | ||
| Q4 24 | -4.5% | 12.7% | ||
| Q3 24 | 7.0% | 8.1% | ||
| Q2 24 | -1.4% | 20.5% |
资本支出强度BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 10.8% | ||
| Q3 25 | 0.8% | 3.4% | ||
| Q2 25 | 0.1% | 15.2% | ||
| Q1 25 | 0.1% | 29.4% | ||
| Q4 24 | 0.5% | 22.1% | ||
| Q3 24 | 0.1% | 28.9% | ||
| Q2 24 | 0.1% | 16.6% |
现金转化率BCRXDOCN
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 2.23× | ||
| Q3 25 | 3.23× | 0.60× | ||
| Q2 25 | 8.12× | 2.50× | ||
| Q1 25 | -859.91× | 1.68× | ||
| Q4 24 | — | 3.91× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 3.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
